Leidos Biomedical Research, Inc.
Frederick National Laboratory for Cancer Research
P.O. Box B, 8560 Progress Drive
About Leidos Biomedical Research, Inc.
Leidos Biomedical Research, Inc. operates the Frederick National Laboratory for Cancer Research under contract to the National Cancer Institute, National Institutes of Health, U.S. Department of Health and Human Services.
The national lab partners with university, corporate, and government scientists to accelerate research discoveries, develop new technologies, and move new diagnostics and treatments into the clinic to benefit patients with cancer and AIDS.
As a Federally Funded Research and Development Center, the national lab excels at innovation and flexibility of operations, offering scientific depth, cutting-edge technologies, and enabling infrastructure. It is one of about 40 U.S. national laboratories and the only one in the nation devoted exclusively to biomedical research.
View jobs from this company
47 articles with Leidos Biomedical Research, Inc.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 22, 2020.
Leidos (NYSE:LDOS), a FORTUNE ® 500 science and technology leader, today announced that its Xpose portable x-ray system (Xpose XP) was named a Silver 2020 Edison Award™ Winner in the Applied Technology category. The Edison Awards™, named after legendary inventor Thomas Edison , recognize and honor the world's best companies in new
Leidos and Clarify Health Announce Strategic Alliance to Deliver Innovative Analytics Solutions to Healthcare Partners
Leidos will enable its customers to deliver Clarify-generated observed and predictive insights directly into healthcare operations through its careC2 platform.
Acquisition extends QTC's independent medical evaluation coverage area for commercial and federal customers
GeoVax Labs, Inc., a biotechnology company developing human vaccines, announced today that it has expanded its collaboration activities with Leidos, Inc.
The following roundup is a collection of stories dealing with the HIMSS 2019 conference and is appropriate for special sections and for general use.
Leidos announced the company will showcase its solutions for hospitals, health systems, and government customers during the 2019 Healthcare Information and Management Systems Society conference February 11-15 in Orlando.
Leidos announced today that Jason Albanese has been named the Leidos Health Group's senior vice president of business development.
Combined Technologies May Yield Therapies for Multiple Cancer Indications
The United States Department of Energy has awarded the team of Leidos and Battelle a $364.7 million Research Support Services (RSS) contract at the National Energy Technology Laboratory (NETL).
Naval Medical Logistics Command Awards Leidos Contract to Study Health Impact of Undersea Operations on Submariners
Leidos was awarded a follow-on contract by the Naval Medical Logistics Command to support biomedical research and development at its Naval Submarine Medical Research Laboratory (NSMRL).
Revenues: $2.53 billion
Cambridge Research Biochemicals to Support Preclinical Study on Treatment for Vision-Damaging Eye Disease
Cambridge Research Biochemicals® will support evaluation of a potential new treatment approach for Fuchs Dystrop.
The follow-on single-award time & materials contract has a one year-base period, four one-year options, and a total contract value of $26M.
The two companies will expands its collaboration to develop preventative, peptide-based malaria vaccine candidates.
Leidos Announces Appointment of Ethan Dmitrovsky, M.D. as President of Leidos Biomedical Research and Laboratory Director of the Frederick National Laboratory for Cancer Research
Leidos announced today that Ethan Dmitrovsky, M.D. was appointed President of subsidiary Leidos Biomed and Laboratory Director of the FNLCR.
PositiveID (PSID) Announces Teaming Agreement With SAIC-Frederick, Inc. to Pursue Defense Threat Reduction Agency Contracts